Inventor · disambiguated record
Andreas Menrad
Also filed as: MENRAD ANDREAS
26 granted patents·21 pending applications·458 citations·filing 1996–2021
97Inventor score
Top patents by PatentIndex Score
47 records- 0195US6448277B2VEGF receptor tyrosine kinase inhibitorsNOVARTIS AG·Filed 2001·Granted Sep 10, 2002·64 cites·19 claims
- 0294US6878720B2VEGF receptor tyrosine kinase inhibitorsNOVARTIS AG·Filed 2002·Granted Apr 12, 2005·50 cites·16 claims
- 0393US7129254B2Effector conjugates, process for their production and their pharmaceutical useSCHERING AG·Filed 2003·Granted Oct 31, 2006·51 cites·15 claims
- 0492US11186638B2Anti-αβTCR antibodyGENZYME CORP·Filed 2018·Granted Nov 30, 2021·10 cites·11 claims
- 0589US7002022B2N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGFSCHERING AG·Filed 2004·Granted Feb 21, 2006·24 cites·8 claims
- 0689US6818661B2Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitorsNOVARTIS AG·Filed 2001·Granted Nov 16, 2004·21 cites·5 claims
- 0786US7122547B1Anthranilic acid amides and the use thereof as medicamentsNOVARTIS AG·Filed 1999·Granted Oct 17, 2006·79 cites·14 claims
- 0884US7148357B2VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinesSCHERING AG·Filed 2003·Granted Dec 12, 2006·15 cites·3 claims
- 0983US7335775B2Effector conjugates, process for their production and their pharmaceutical useSCHERING AG·Filed 2006·Granted Feb 26, 2008·5 cites·7 claims
- 1083US7202260B2VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridonesSCHERING AG·Filed 2004·Granted Apr 10, 2007·11 cites·14 claims
- 1183US6376480B1Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agentsSCHERING AG·Filed 2000·Granted Apr 23, 2002·18 cites·17 claims
- 1281US7851599B2Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabinePHILOGEN SPA·Filed 2007·Granted Dec 14, 2010·10 cites·20 claims
- 1381US7615565B2VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinesBAYER SCHERING PHARMA AG·Filed 2006·Granted Nov 10, 2009·3 cites·9 claims
- 1481US7012081B2Anthranyl amides and their use as medicamentsSCHERING AG·Filed 2001·Granted Mar 14, 2006·14 cites·12 claims
- 1580US10017573B2Anti-αβTCR antibodySNELL DANIEL·Filed 2012·Granted Jul 10, 2018·8 cites·12 claims
- 1678US7429592B2Cyanoanthranilamide derivatives and the use thereof as medicamentsSCHERING AG·Filed 2002·Granted Sep 30, 2008·12 cites·10 claims
- 1776US11142575B2Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptideGENZYME CORP·Filed 2014·Granted Oct 12, 2021·3 cites·11 claims
- 1876US7081468B2Ortho-substituted anthranilic acid amides and their use as medicamentsSCHERING AG·Filed 2001·Granted Jul 25, 2006·8 cites·4 claims
- 1974US7459470B2N-oxide anthranylamide derivatives and their use as medicamentsSCHERING AG·Filed 2002·Granted Dec 2, 2008·8 cites·10 claims
- 2069US2022153841A1Anti-alphabetatcr antibodyGENZYME CORP·Filed 2021·Application pending·0 cites
- 2166US6372731B1Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicamentsSCHERING AG·Filed 1996·Granted Apr 16, 2002·21 cites·6 claims
- 2264US6344339B1Monoclonal antibodies against the extracellular domain of human VEGF-receptor protein (KDR)SCHERING AG·Filed 1997·Granted Feb 5, 2002·23 cites·18 claims
- 2363US8796426B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartNERI DARIO·Filed 2008·Granted Aug 5, 2014·0 cites·18 claims
- 2460US2008166362A1New effector conjugates, process for their production and their pharmaceutical useBERGER MARKUS·Filed 2007·Application pending·0 cites
- 2559US9289470B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartPHILOGEN SPA·Filed 2014·Granted Mar 22, 2016·0 cites·29 claims
- 2659US2010310454A1Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and /or their cancerous counterpartNERI DARIO·Filed 2008·Application pending·0 cites
- 2757US2022098299A1Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptideGENZYME CORP·Filed 2021·Application pending·0 cites
- 2857US2006074112A1N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitorsALTMANN KARL-HEINZ·Filed 2005·Application pending·0 cites
- 2957US2006287339A1Aza- and polyazanthranyl amides and their use as medicamentsSEIDELMANN DIETER·Filed 2006·Application pending·0 cites
- 3056US2007135489A1Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridonesHUTH ANDREAS·Filed 2007·Application pending·0 cites
- 3155US2009117073A1Use of a fusion protein targeting the ed-b fibronectin domain for treatment of atherosclerosisMENRAD ANDREAS·Filed 2007·Application pending·0 cites
- 3253US7479491B2Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitorsNOVARTIS AG·Filed 2004·Granted Jan 20, 2009·0 cites·3 claims
- 3353US2005064512A1Emitter-binding peptides that produce a change in the spectral emission properties of the emitterFiled 2004·Application pending·0 cites
- 3452US2004039019A1Selected anthranilaminde pyridinamides and their use as pharmaceutical agentsSCHERING AG·Filed 2003·Application pending·0 cites
- 3550US2011071165A1Aza- and polyazanthranyl amides and their use as medicamentsNOVARTIS AG·Filed 2010·Application pending·0 cites
- 3649US2004224968A1Aza-and polyazanthranyl amides and their use as medicamentsFiled 2001·Application pending·0 cites
- 3746US2009137002A1Anti ephb4 antibodies and antibody fragmentsPETRUL HEIKE·Filed 2008·Application pending·0 cites
- 3845US7517894B2VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinesBAYER SCHERING PHARMA AG·Filed 2004·Granted Apr 14, 2009·0 cites·11 claims
- 3943US2005261343A1Anthranilamides and their use as pharmaceutical agentsKRUEGER MARTIN·Filed 2005·Application pending·0 cites
- 4043US2009081207A1High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicityMENRAD ANDREAS·Filed 2007·Application pending·0 cites
- 4143US2006014747A1Ortho-substituted anthranilic acid amides and their use as pharmaceutical agentsKRUEGER MARTIN·Filed 2005·Application pending·0 cites
- 4241US2005221434A1Receptor of the EDb-fibronectin domainsMENRAD ANDREAS·Filed 2005·Application pending·0 cites
- 4341US2005089941A1Receptor of the EDb-fibronectin domainsFiled 2003·Application pending·0 cites
- 4440US2002197700A1Receptor of the EDb-fibronectin domainsSCHERING AG·Filed 2001·Application pending·0 cites
- 4540US2005234247A1New effector conjugates, process for their production and their pharmaceutical useKLAR ULRICH·Filed 2005·Application pending·0 cites
- 4640US2004254185A1Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3Filed 2002·Application pending·0 cites
- 4739US7785591B2Identification and characterization of function-blocking anti-ED-B-fibronectin antibodiesMORPHOSYS AG·Filed 2005·Granted Aug 31, 2010·0 cites·26 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →